Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients
Authors
Keywords
-
Journal
WIENER KLINISCHE WOCHENSCHRIFT
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-08-10
DOI
10.1007/s00508-020-01720-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China
- (2020) Zunyou Wu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A Systematic Review of Lopinavir Therapy for SARS Coronavirus and MERS Coronavirus–A Possible Reference for Coronavirus Disease‐19 Treatment Option
- (2020) Tian‐Tian Yao et al. JOURNAL OF MEDICAL VIROLOGY
- Clinical Characteristics of Coronavirus Disease 2019 in China
- (2020) Wei-jie Guan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19)
- (2020) Christian Schoergenhofer et al. ANNALS OF INTERNAL MEDICINE
- Factors Associated With Prolonged Viral RNA Shedding in Patients with Coronavirus Disease 2019 (COVID-19)
- (2020) Kaijin Xu et al. CLINICAL INFECTIOUS DISEASES
- The duration of viral shedding of discharged patients with severe COVID-19
- (2020) Bo Zhou et al. CLINICAL INFECTIOUS DISEASES
- Predicting infectious SARS-CoV-2 from diagnostic samples
- (2020) Jared Bullard et al. CLINICAL INFECTIOUS DISEASES
- Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19
- (2020) Adarsh Bhimraj et al. CLINICAL INFECTIOUS DISEASES
- In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
- (2020) Xueting Yao et al. CLINICAL INFECTIOUS DISEASES
- Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis
- (2020) Wei-jie Guan et al. EUROPEAN RESPIRATORY JOURNAL
- Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
- (2020) Philippe Gautret et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
- (2020) Eli S. Rosenberg et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)
- (2020) James M. Sanders et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
- (2020) Ivan Fan-Ngai Hung et al. LANCET
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
- (2020) Fei Zhou et al. LANCET
- Virological assessment of hospitalized patients with COVID-2019
- (2020) Roman Wölfel et al. NATURE
- Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
- (2020) Jason D. Goldman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Remdesivir for the Treatment of Covid-19 — Preliminary Report
- (2020) John H. Beigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
- (2020) Bin Cao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19
- (2020) Joshua Geleris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study
- (2020) Philippe Gautret et al. Travel Medicine and Infectious Disease
- Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China
- (2020) Chaomin Wu et al. JAMA Internal Medicine
- Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro
- (2020) Jia Liu et al. Cell Discovery
- Early Oseltamivir After Hospital Admission Is Associated With Shortened Hospitalization: A 5-Year Analysis of Oseltamivir Timing and Clinical Outcomes
- (2018) Jeremy Katzen et al. CLINICAL INFECTIOUS DISEASES
- Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa
- (2018) Timothy M Uyeki et al. CLINICAL INFECTIOUS DISEASES
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now